{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:36:50Z","timestamp":1785811010591,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.rvsc.2022.06.020","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T21:00:57Z","timestamp":1656709257000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial"],"prefix":"10.1016","volume":"150","author":[{"given":"Guilherme Luiz Carvalho","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Meirelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Castilhos","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemir Santiago","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Viau","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco S\u00e1vio","family":"de Moura Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fab\u00edola Peixoto","family":"da Silva Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"de Faria Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lan Gomes","family":"P\u00f6ppl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rvsc.2022.06.020_bb0005","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jvim.14528","article-title":"Comparison of 2 doses for ACTH stimulation testing in dogs suspected of or treated for hyperadrenocorticism","volume":"30","author":"Aldridge","year":"2016","journal-title":"J. Vet. Intern. Med."},{"issue":"5","key":"10.1016\/j.rvsc.2022.06.020_bb0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1517\/13543784.17.5.669","article-title":"Pituitary-targeted medical therapy of Cushing\u2019s disease","volume":"17","author":"Alexandraki","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.rvsc.2022.06.020_bb0015","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jvim.12192","article-title":"Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal)","volume":"27","author":"Behrend","year":"2013","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2019.105342","article-title":"Diagnosis of spontaneous hyperadrenocorticism in dogs. Part 1: pathophysiology, aetiology, clinical and clinicopathological features","volume":"252","author":"Bennaim","year":"2019","journal-title":"Vet. J."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/jvim.12357","article-title":"Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism","volume":"28","author":"Bonadio","year":"2014","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1751-0813.2004.tb12702.x","article-title":"Medical treatment of hyperadrenocorticism in the dog","volume":"82","author":"Braddock","year":"2003","journal-title":"Aust. Vet. J."},{"issue":"5","key":"10.1016\/j.rvsc.2022.06.020_bb0035","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1751-0813.2004.tb12702.x","article-title":"Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism","volume":"82","author":"Braddock","year":"2004","journal-title":"Aust. Vet. J."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0195-5616(97)50031-3","article-title":"Management of canine pituitary-dependent hyperadrenocorticism with L-Deprenyl (Anypryl)","volume":"27","author":"Bruyette","year":"1997","journal-title":"Vet. Clin. N. Am-Small."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.domaniend.2010.10.002","article-title":"Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats","volume":"40","author":"Burkhardt","year":"2011","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rvsc.2009.07.005","article-title":"Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities","volume":"88","author":"Castillo","year":"2010","journal-title":"Res. Vet. Sci."},{"issue":"9","key":"10.1016\/j.rvsc.2022.06.020_bb0055","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","article-title":"Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs","volume":"147","author":"Castillo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.rvsc.2022.06.020_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.rvsc.2007.08.009","article-title":"Cushing\u2019s disease in dogs: cabergoline treatment","volume":"85","author":"Castillo","year":"2008","journal-title":"Res.Vet. Sci."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0065","first-page":"124","article-title":"Effect of SOM230 (Pasireotide) on corticotropic cells: action in dogs with Cushing\u2019s disease","volume":"34","author":"Castillo","year":"2011","journal-title":"Res. Vet. Sci."},{"issue":"6","key":"10.1016\/j.rvsc.2022.06.020_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1748-5827.2004.tb00241.x","article-title":"Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism","volume":"45","author":"Chapman","year":"2004","journal-title":"J. Small Anim. Pract."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jveb.2021.07.014","article-title":"Cognitive dysfunction severity evaluation in dogs with naturally-occurring Cushing\u2019s syndrome: a matched case-control study","author":"Da Silva","year":"2021","journal-title":"J. Vet. Behavior"},{"issue":"9","key":"10.1016\/j.rvsc.2022.06.020_bb0080","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1210\/en.2008-0244","article-title":"Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing\u2019s disease","volume":"149","author":"De Bruin","year":"2015","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.rvsc.2022.06.020_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1151-1","article-title":"New avenues in the medical treatment of Cushing\u2019s disease: corticotroph tumor targeted therapy","volume":"114","author":"Fleseriu","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0090","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tvjl.2008.10.007","article-title":"Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hyperadrenocorticism","volume":"183","author":"Galac","year":"2010","journal-title":"Vet. J."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0095","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jvim.14357","article-title":"What\u2019s in a name? Classification of diabetes mellitus in veterinary medicine and why it matters","volume":"30","author":"Gilor","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jvim.14608","article-title":"Clinical relationship between cholestatic disease and pituitary-dependent hyperadrenocorticism in dogs: a retrospective case series","volume":"31","author":"Kim","year":"2017","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tvjl.2017.10.018","article-title":"Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane","volume":"230","author":"King","year":"2017","journal-title":"Vet. J."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000094325","article-title":"New aspects in the diagnosis and treatment of Cushing\u2019s disease","volume":"35","author":"Labeur","year":"2006","journal-title":"Front. Horm. Res."},{"issue":"3","key":"10.1016\/j.rvsc.2022.06.020_bb0120","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.pnpbp.2004.12.012","article-title":"Therapeutic agents for the treatment of cognitive dysfunction syndrome in senior dogs","volume":"29","author":"Landsberg","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.rvsc.2022.06.020_bb0125","first-page":"138","article-title":"Study of the effect of total serum protein and albumin concentrations on canine fructosamine concentration","volume":"63","author":"Loste","year":"1999","journal-title":"Can. J. Vet. Res."},{"issue":"11","key":"10.1016\/j.rvsc.2022.06.020_bb0130","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2460\/javma.252.11.1403","article-title":"Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015)","volume":"252","author":"Lottati","year":"2018","journal-title":"J. Am. Vet. Med. A."},{"issue":"23","key":"10.1016\/j.rvsc.2022.06.020_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/vr.103744","article-title":"Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs","volume":"179","author":"Macfarlane","year":"2016","journal-title":"Vet. Rec."},{"issue":"6","key":"10.1016\/j.rvsc.2022.06.020_bb0140","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1740-8261.2003.tb00531.x","article-title":"Changes in ultrasonographic appearance of adrenal glands in d.ogs with hyperadrenocorticism treated with trilostane","volume":"44","author":"Mantis","year":"2003","journal-title":"Vet. Radiol. Ultrasoun."},{"issue":"6","key":"10.1016\/j.rvsc.2022.06.020_bb0145","first-page":"735","article-title":"Advances in evaluation of cognitive impairment in patients with Cushing\u2019s disease","volume":"38","author":"Mao","year":"2016","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao."},{"issue":"3","key":"10.1016\/j.rvsc.2022.06.020_bb0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1590\/s0100-736x2017000300007","article-title":"Use of low-dose of synthetic ACTH in the adrenal stimulation test for diagnosis and monitoring of canine hyperadrenocorticism: evaluation of diagnostic efficacy","volume":"37","author":"Martins","year":"2017","journal-title":"Pesqui. Vet. Bras."},{"issue":"1","key":"10.1016\/j.rvsc.2022.06.020_bb0155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.rvsc.2011.07.003","article-title":"Low dose of insulin detemir controls glycaemia, insulinemia and prevents diabetes mellitus progression in the dog with pituitary-dependent hyperadrenocorticism","volume":"93","author":"Miceli","year":"2012","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0160","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rvsc.2017.07.026","article-title":"Concurrent hyperadrenocorticism and diabetes mellitus in dogs","volume":"115","author":"Miceli","year":"2017","journal-title":"Res. Vet. Sci."},{"issue":"2\u20133","key":"10.1016\/j.rvsc.2022.06.020_bb0165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0091-3057(94)00417-H","article-title":"Effects of chronic L-Deprenyl oral administration in dogs","volume":"51","author":"Milgram","year":"1995","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.rvsc.2022.06.020_bb0170","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0278-5846(01)00205-6","article-title":"The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation","volume":"25","author":"Mills","year":"2001","journal-title":"Prog. Neuro-Psychoph."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1999.tb02183.x","article-title":"Medical treatment of pituitary-dependent hyperadrenocorticism in dogs: should L-Deprenyl (Anypryl) ever be used?","volume":"13","author":"Peterson","year":"1999","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0180","first-page":"1379","article-title":"Frequency of endocrinopathies and characteristics of affected dogs and cats in southern Brazil (2004-2014)","volume":"44","author":"P\u00f6ppl","year":"2016","journal-title":"Acta Sci. Vet."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0185","doi-asserted-by":"crossref","DOI":"10.1590\/0103-8478cr20200282","article-title":"Canine endogenous adrenocorticotrophic hormone preanalytical stability after sample shipping in dry ice or recyclable ice bars","volume":"51","author":"P\u00f6ppl","year":"2021","journal-title":"Cienc. Rural."},{"issue":"2","key":"10.1016\/j.rvsc.2022.06.020_bb0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cvsm.2009.10.008","article-title":"Trilostane in dogs","volume":"40","author":"Ramsey","year":"2010","journal-title":"Vet. Clin. N. Am-Small."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000443868","article-title":"Cortisol excess and the brain","volume":"46","author":"Resmini","year":"2016","journal-title":"Front. Horm. Res."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0200","first-page":"291","article-title":"The efficacy of L-Deprenyl in dogs with pituitary-dependent hyperadrenocorticism","volume":"13","author":"Reusch","year":"1999","journal-title":"J. Vet. Intern. Med."},{"issue":"20","key":"10.1016\/j.rvsc.2022.06.020_bb0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/vr.122.20.486","article-title":"An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism","volume":"122","author":"Rijnberk","year":"1988","journal-title":"Vet. Rec."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1677\/joe.0.1180271","article-title":"Effects of bromocriptine on corticotropin, melanotropin, and corticosteroid secretion in dogs with pituitary-dependent hyperadrenocorticism","volume":"118","author":"Rijnberk","year":"1988","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0215","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ijbiomac.2018.11.188","article-title":"Identification of differences in the formation of plasma glycated proteins between dogs and humans under diabetes-like glucose concentration conditions","volume":"123","author":"Rivera-Velez","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.rvsc.2022.06.020_bb0220","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2460\/ajvr.2002.63.506","article-title":"Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane","volume":"63","author":"Ruckstuhl","year":"2002","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0225","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0024-3205(97)00611-5","article-title":"Treatment with L-Deprenyl prolongs life in elderly dogs","volume":"61","author":"Ruehl","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0230","first-page":"316","article-title":"Therapeutic action of L-Deprenyl in dogs: a model of human brain aging","volume":"45","author":"Ruehl","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0235","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tvjl.2018.09.014","article-title":"Treating canine Cushing\u2019s syndrome: current options and future prospects","volume":"241","author":"Sanders","year":"2018","journal-title":"Vet. J."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.rvsc.2018.04.015","article-title":"Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenomas in dogs","volume":"119","author":"Sato","year":"2018","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0245","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/jvim.15639","article-title":"Development and evaluation of a health-related quality-of-life tool for dogs with Cushing\u2019s syndrome","volume":"33","author":"Schofield","year":"2019","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.domaniend.2005.09.004","article-title":"Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane","volume":"31","author":"Sieber-Ruckstuhl","year":"2006","journal-title":"Domest. Anim. Endocrinol."},{"issue":"3","key":"10.1016\/j.rvsc.2022.06.020_bb0255","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/vru.12236","article-title":"Ultrasonographic evaluation of adrenal gland size compared to body weight in normal dogs","volume":"56","author":"Soulsby","year":"2014","journal-title":"Vet. Radiol. Ultrasound."},{"key":"10.1016\/j.rvsc.2022.06.020_bb0260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.domaniend.2008.10.002","article-title":"Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis","volume":"36","author":"Teshima","year":"2009","journal-title":"Domest. Anim. Endocrinol."},{"issue":"11","key":"10.1016\/j.rvsc.2022.06.020_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0166267","article-title":"Carbenoxolone disodium treatment for canine pituitary-dependent hyperadrenocorticism","volume":"11","author":"Teshima","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.rvsc.2022.06.020_bb0270","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jsap.12396","article-title":"Canine hyperlipidaemia","volume":"56","author":"Xenoulis","year":"2015","journal-title":"J. Small Anim. Pract."},{"issue":"2","key":"10.1016\/j.rvsc.2022.06.020_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/vetr.244","article-title":"Evaluation of fructosamine concentration as an index marker for glycaemic control in diabetic dogs","volume":"190","author":"Zeugswetter","year":"2022","journal-title":"Vet. Rec."}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528822001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528822001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:27:36Z","timestamp":1758515256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034528822001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":54,"alternative-id":["S0034528822001746"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2022.06.020","relation":{},"ISSN":["0034-5288"],"issn-type":[{"value":"0034-5288","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2022.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}